PCSK9 Protein (AA 151-811) (His tag)

Catalog No. ABIN7275414

Product Details

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Protein Type: Recombinant

Protein Characteristics: AA 151-811

Origin: Cynomolgus

Source: HEK-293 Cells

Purification tag / Conjugate: This PCSK9 protein is labelled with His tag.

Purpose: Cynomolgus PCSK9 Protein

Sequence: Glu151-Gln811

Characteristics: Recombinant Cynomolgus PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Glu151-Gln811.

Purity: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1EU per μg by the LAL method.

Biological Activity Comment: The affinity constant of 0.27 nM as determined in SPR assay (Biacore T200). See testing image for detail.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Alternative Name: PCSK9 (PCSK9 Products)

Synonyms: FH3 Protein, HCHOLA3 Protein, LDLCQ1 Protein, NARC-1 Protein, NARC1 Protein, PC9 Protein, AI415265 Protein, AI747682 Protein, Narc1 Protein, proprotein convertase subtilisin/kexin type 9 Protein, proprotein convertase subtilisin/kexin type 9 L homeolog Protein, PCSK9 Protein, pcsk9.L Protein, pcsk9 Protein, Pcsk9 Protein

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

Molecular Weight: Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Tris-Bis PAGE result.

UniProt: A0A2K5TZC4